ImmunityBio Inc. (IBRX) 12-Month Stock Forecast & Price Target Cone
ImmunityBio Inc. (IBRX) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Drag to Test Your IBRX Position Size: $10,000
Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)
Street Historical Accuracy: 64/100| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| Morgan StanleyInstitutional Equity Desk | HOLD | $9 | 74% | A |
| Goldman SachsSector Coverage Lead | UNDERPERFORM | $12 | 69% | B |
| JP MorganUS Large-Cap Research | SELL | $8 | 58% | C |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring IBRX)
- ✓Live walkthrough of IBRX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
IBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IBRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IBRX. Explore sector supply chains on /butterfly.
IBRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is IBRX's 12-month stock price target?
ImmunityBio Inc. (IBRX) carries a 12-month consensus base price target of $8.62 (-1.4% from $8.74), with a bull-case target of $13.05 and a bear-case floor of $6.72.
Is IBRX stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates IBRX D+ (Sell — SELL) with an RQD Confidence score of 55/100.